Myasthenia gravis (MG): investigational treatments

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Myasthenia gravis (MG): investigational treatments. Adequate concentrations are essential for treatment response. Fully referenced neurology checklist.

Tacrolimus

  • This is especially effective if anti RyR antibodies are positive
  • Adequate concentrations are essential for treatment response

Anti-human neonatal Fc receptor (FcRn) monoclonal antibodies

Locked: subscribe to see this section.

Anti C5 monoclonal antibodies

Locked: subscribe to see this section.

Anti CD20 monoclonal antibodies

Locked: subscribe to see this section.

Other investigational drugs

Locked: subscribe to see this section.

Other investigational interventions

Locked: subscribe to see this section.

References

  1. Jordan A, Freimer M. Recent advances in understanding and managing myasthenia gravis. F1000Res 2018; 7. pii: F1000 Faculty Rev-1727.
  2. Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies directed against b-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs 2019; 79:353-364. 
  3. Wolfe GI, Ward ES, de Haard H, Ulrichts P, Mozaffar T, Pasnoor M, Vidarsson G. IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis. J Neurol Sci 2021; 430:118074. 
  4. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175:408-418.
  5. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 2018; 11:1756285617749134.
  6. And 27 more. Subscribe to see the full list

Related checklists

Loading...